• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Globalisation and blood safety.

作者信息

Farrugia Albert

机构信息

Blood and Tissues Unit, Australian Therapeutic Goods Administration, ACT, Australia.

出版信息

Blood Rev. 2009 May;23(3):123-8. doi: 10.1016/j.blre.2008.10.004. Epub 2008 Dec 9.

DOI:10.1016/j.blre.2008.10.004
PMID:19081166
Abstract

Globalisation may be viewed as the growing interdependence of countries worldwide through the increasing volume and variety of cross-border transactions in goods and services, and also through the more rapid and widespread diffusion of technology. Globalisation is not just an economic phenomenon, although it is frequently described as such, but includes commerce, disease and travel, and immigration, and as such it affects blood safety and supply in various ways. The relatively short travel times offered by modern aviation can result in the rapid spread of blood-borne pathogens before measures to counteract transmission can be put in place; this would have happened with SARS if the basic life cycle of the SARS virus included an asymptomatic viraemia. This risk can be amplified by ecological factors which effect the spread of these pathogens once they are transferred to a naïve ecosystem, as happened with West Nile Virus (WNV) in North America. The rationalization and contraction of the plasma products industry may be viewed as one aspect of globalisation imposed by the remorseless inevitability of the market; the effect of this development on the safety and supply of products has yet to be seen, but the oversight and assurance of a shrinking number of players will present particular challenges. Similarly, the monopolization of technology, through patent enforcement which puts access beyond the reach of developing countries, can have an effect on blood safety. The challenges presented to blood safety by globalisation are heightening the tensions between the traditional focus on the product safety - zero risk paradigm and the need to view the delivery of safe blood as an integrated process. As an illustration of this tension, donor deferral measures imposed by globalisation-induced risks such as vCJD and WNV have resulted in the loss of the safest and most committed portion of the blood donor population in many Western countries, leading to an increased risk to safety and supply. It is only through an appreciation of the basic needs of transfusion medicine, including the enunciation of appropriate principles to manage, rather than eliminate, risks, that the challenges imposed by globalisation may be overcome.

摘要

相似文献

1
Globalisation and blood safety.
Blood Rev. 2009 May;23(3):123-8. doi: 10.1016/j.blre.2008.10.004. Epub 2008 Dec 9.
2
Globalization and blood safety.全球化与血液安全。
ISBT Sci Ser. 2006 Sep;1(1):25-32. doi: 10.1111/j.1751-2824.2006.00007.x. Epub 2006 Aug 15.
3
Safety and supply of haemophilia products: worldwide perspectives.
Haemophilia. 2004 Jul;10(4):327-33. doi: 10.1111/j.1365-2516.2004.00910.x.
4
Reengineering transfusion and cellular therapy processes hospitalwide: ensuring the safe utilization of blood products.在全院范围内重新设计输血和细胞治疗流程:确保安全使用血液制品。
Transfusion. 2005 Oct;45(4 Suppl):159S-71S. doi: 10.1111/j.1537-2995.2005.00617.x.
5
Developing an administrative plan for transfusion medicine--a global perspective.制定输血医学管理计划——全球视角
Transfusion. 2005 Oct;45(4 Suppl):224S-40S. doi: 10.1111/j.1537-2995.2005.00621.x.
6
Regulatory challenges to global harmonization and expanded access to concentrates: how will regulators balance the increasing cost of new safety requirements with the desire to increase the availability of affordable product?全球协调和扩大浓缩物获取途径所面临的监管挑战:监管机构将如何在新安全要求成本不断增加与提高可负担产品可得性的愿望之间取得平衡?
Haemophilia. 2004 Oct;10 Suppl 4:83-7. doi: 10.1111/j.1365-2516.2004.01040.x.
7
Challenges in global blood safety.全球血液安全面临的挑战。
World Hosp Health Serv. 2004;40(1):45-9, 51, 52.
8
Availability, safety and quality of blood for transfusion in the Americas.美洲地区用于输血的血液的可及性、安全性和质量。
World Hosp Health Serv. 2005;41(1):25, 27-31.
9
[Safety of blood transfusion at the international level. The role of WHO].[国际层面的输血安全。世界卫生组织的作用]
Transfus Clin Biol. 2006 Sep;13(3):200-2. doi: 10.1016/j.tracli.2006.07.007. Epub 2006 Sep 26.
10
Transfusion safety: Where are we today?输血安全:我们如今处于什么状况?
Ann N Y Acad Sci. 2005;1054:325-41. doi: 10.1196/annals.1345.040.

引用本文的文献

1
The Evolution of the Safety of Plasma Products from Pathogen Transmission-A Continuing Narrative.血浆制品病原体传播安全性的演变——持续的叙述
Pathogens. 2023 Feb 15;12(2):318. doi: 10.3390/pathogens12020318.
2
The Mirasol Evaluation of Reduction in Infections Trial (MERIT): study protocol for a randomized controlled clinical trial.Mirasol 降低感染评估试验(MERIT):一项随机对照临床试验的研究方案。
Trials. 2022 Apr 4;23(1):257. doi: 10.1186/s13063-022-06137-8.
3
Spatiotemporal Distribution of Zika Virus and Its Spatially Heterogeneous Relationship with the Environment.
寨卡病毒的时空分布及其与环境的空间异质性关系。
Int J Environ Res Public Health. 2021 Jan 2;18(1):290. doi: 10.3390/ijerph18010290.
4
Manufacture of immunoglobulin products for patients with primary antibody deficiencies - the effect of processing conditions on product safety and efficacy.用于原发性抗体缺陷患者的免疫球蛋白产品的生产——加工条件对产品安全性和有效性的影响。
Front Immunol. 2014 Dec 23;5:665. doi: 10.3389/fimmu.2014.00665. eCollection 2014.
5
Revaluing donor and recipient bodies in the globalised blood economy: transitions in public policy on blood safety in the United Kingdom.在全球化的血液经济中重新评估供体和受体:英国血液安全公共政策的转变。
Health (London). 2014 Jan;18(1):79-94. doi: 10.1177/1363459313476966. Epub 2013 Mar 6.
6
Is self-sufficiency in haemotherapies a practical or necessary goal?血液疗法的自给自足是一个切实可行或必要的目标吗?
Blood Transfus. 2013 Apr;11(2):183-92. doi: 10.2450/2012.0148-12. Epub 2012 Dec 13.
7
Alternative blood products and clinical needs in transfusion medicine.替代血液制品与输血医学的临床需求。
Stem Cells Int. 2012;2012:639561. doi: 10.1155/2012/639561. Epub 2012 Apr 8.